IMS 2025: Bispecific Antibodies in Multiple Myeloma Immunotherapy
Okay, here’s a breakdown of the provided text, focusing on the interview content. It appears to be a transcript of an interview with Dr. karen Rodriguez-Lorenc, a therapeutic area lead at Regeneron, discussing new immunotherapy approaches for multiple myeloma.
Key Takeaways from the Interview:
* Dr. Rodriguez-Lorenc’s Role: She is the therapeutic area lead for hemato-oncology at Regeneron.
* Current State of Multiple Myeloma Treatment: Treatment is improving with T-cell engagers and CAR-T therapy, but there’s still a need for deeper and more durable responses.
* Costimulatory bispecific Antibodies - The “Next Step”: These are being explored to potentially achieve those deeper and longer-lasting responses. The idea is to build on the success of existing therapies.
* How They Differ from Existing Bispecifics: The current bispecifics (like linvoseltamab) target BCMA on the myeloma cell and CD3 on the T cell. The new generation aims to add a costimulatory element to enhance the T-cell activation and effectiveness.
* Mechanism Explanation (Partial): The interview begins to explain the format of these bispecifics and their targets.
In essence, the interview is introducing a new generation of immunotherapies for multiple myeloma that aim to improve upon existing treatments by enhancing T-cell activity thru costimulation.
Additional Notes:
* The text includes some HTML-like tags (<p class="">, <strong><em>, etc.) suggesting it’s extracted from a web page.
* There’s also some data at the very beginning that looks like JSON or a data structure used by a website framework (likely Astro, based on the tags). This data isn’t part of the interview content itself.
* The name “Royaly-Lorance” appears to be a typo for “Rodriguez-Lorenc”.
* The interview is cut off mid-sentence (“What it do…”).